Drug delivery systems for the eye

Expert Review of Medical Devices

Volumn 6, Issue 3, 2009, Pages 277-290

  Kearns, Victoria R ^a   Williams, Rachel L ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Combinational devices; Devices; Ocular drug delivery

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; CORTICOSTEROID; CYCLOSPORIN A; DAUNORUBICIN; DEXAMETHASONE; ETHYLENE VINYL ACETATE COPOLYMER; EYE DROPS; FLUOCINOLONE ACETONIDE; FLUOROURACIL; GANCICLOVIR; HERBIMYCIN A; HYPERICIN; IMMUNOSUPPRESSIVE AGENT; LATANOPROST; MITOMYCIN C; PEGAPTANIB; PILOCARPINE; POLYCAPROLACTONE; POLYGLACTIN; POLYGLYCOLIC ACID; POLYVINYL ALCOHOL; PREDNISOLONE; RANIBIZUMAB; RETINOIC ACID; STEROID; SURODEX; TIMOLOL; TRANILAST; TRIAMCINOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BLOOD RETINA BARRIER; CATARACT; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DIABETIC MACULAR EDEMA; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; EYE DISEASE; EYE INFLAMMATION; FILM; GENE THERAPY; GLAUCOMA; HUMAN; IMPLANT; INTRAOCULAR PRESSURE; IONTOPHORESIS; LENS IMPLANT; LONG TERM EXPOSURE; MATERIAL COATING; NONHUMAN; RETINA MACULA AGE RELATED DEGENERATION; RETINITIS; REVIEW; SCAR FORMATION; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; SYSTEMIC THERAPY; TRABECULECTOMY; VITREORETINOPATHY; ANIMAL; INSTRUMENTATION; METHODOLOGY;

ANIMALS; DRUG DELIVERY SYSTEMS; EYE DISEASES; HUMANS;

EID: 67651025118     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/erd.09.4     Document Type: Review

References (102)

1. Saika S. Relationship between posterior capsule opacification and intraocular lens biocompatibility. Prog. Retin. Eye Res. 23(3), 283-305 (2004).
2. Cordeiro MF. Beyond mitomycin: TGF-β and wound healing. Prog. Retin. Eye Res. 21(1), 75-89 (2002).
3. Pastor JC. Proliferative vitreoretinopathy: an overview. Surv. Ophthalmol. 43(1), 3-18 (1998).
4. Guidetti B, Azema J, Malet-Martino M, Martino R. Delivery systems for the treatment of proliferative vitreoretinopathy: materials, devices and colloidal carriers. Curr. Drug Deliv. 5(1), 7-19 (2008).
5. Sun JK, Arroyo JG. Adjunctive therapies for proliferative vitreoretinopathy. Int. Ophthalmol. Clin. 44(3), 1-10 (2004).
6. Young TA, D'Amico DJ. Controversies in proliferative vitreoretinopathy tamponade and pharmacologic adjuvants. Int. Ophthalmol. Clin. 45(4), 163-171 (2005).
7. Borhani H, Peyman GA, Rahimy MH, Thompson H. Suppression of experimental proliferative vitreoretinopathy by sustained intraocular delivery of 5-FU. Int. Ophthalmol. 19(1), 43-49 (1995).
8. Chang YC, Hu DN, Wu WC. Effect of Oral 13-cis-retinoic acid treatment on postoperative clinical outcome of eyes with proliferative vitreoretinopathy. Am. J. Ophthalmol. 146(3), 440-446 (2008).
9. Schiff WM, Hwang JC, Ober MD et al. Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy. Arch. Ophthalmol. 125(9), 1161-1167 (2007).
10. Simó R, Hernández C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 51(9), 1574-1580 (2008).
11. Kottler UB, Junemann AGM, Aigner T et al. Comparative effects of TGF-β1 and TGF-β2 on extracellular matrix production, proliferation, migration, and collagen contraction of human Tenon's capsule fibroblasts in pseudoexfoliation and primary open-angle glaucoma. Exp. Eye Res. 80(1), 121-134 (2005).
12. Saika S, Yamanaka O, Kawashima Y et al. OPC-15161 suppresses the proliferation of Tenon's capsule fibroblasts and the production of type I collagen and fibronectin stimulated by TGF-β1 in vitro. Curr. Eye Res. 17(9), 933-940 (1998).
13. Singh N, Amin S, Richter E et al. Flt-1 Intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo. Invest. Ophthalmol. Vis. Sci. 46(5), 1647-1652 (2005).
14. Kim B, Tang Q, Biswas PS et al. Inhibition of Ocular Angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am. J. Pathol. 165(6), 2177-2185 (2004).
15. Colella P, Cotugno G, Auricchio A. Ocular gene therapy: current progress and future prospects. Trends Mol. Med. 15(1), 23-31 (2009).
16. MacLaren RE, Pearson RA, MacNeil A et al. Retinal repair by transplantation of photoreceptor precursors. Nature 444(7116), 203-207 (2006).
17. Shortt AJ, Secker GA, Notara MD et al. Transplantation of ex vivo cultured limbal epithelial stem cells: a review of techniques and clinical results. Surv. Ophthalmol. 52(5), 483-502 (2007).
18. Kano T, Abe T, Tomita H et al. Protective effect against ischemia and light damage of iris pigment epithelial cells transfected with the BDNF gene. Invest. Ophthalmol. Vis. Sci. 43(12), 3744-3753 (2002).
19. da Cruz L, Chen FK, Ahmado A, Greenwood J, Coffey P. RPE transplantation and its role in retinal disease. Prog. Retin. Eye Res. 26(6), 598-635 (2007).
20. Kruse F, Cursiefen C. Surgery of the cornea: corneal, limbal stem cell and amniotic membrane transplantation. Dev. Ophthalmol. 41, 159-170 (2008).
21. Notara M, Daniels JT. Biological principals and clinical potentials of limbal epithelial stem cells. Cell Tissue Res. 331(1), 135-143 (2008).
22. Kovoor TA, Kim AS, McCulley JP et al. Evaluation of the corneal effects of topical ophthalmic fluoroquinolones using in vivo confocal microscopy. Eye Contact Lens 30(2), 90-94 (2004).
23. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 23(5), 490-496 (2004).
24. Zhang W, Prausnitz MR, Edwards Al. Model of transient drug diffusion across cornea. J. Control. Release 99(2), 241-258 (2004).
25. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J. Pharm. Sci. 87(12), 1479-1488 (1998).
26. Mochizuki M, Nakagami T, Asai T et al. Two cases of corneal ulcer following instillation of bromfenac sodium ophthalmic solution. Rinsho Ganka 57(5), 675-679 (2003).
27. Pfister RR. Permanent corneal edema resulting from the treatment of PTK corneal haze with mitomycin: a case report. Cornea 23(7), 744-747 (2004).
28. Mindel JS, Smith H, Jacobs M, Kharlamb AB, Friedman AH. Drug reservoirs in topical therapy. Invest. Ophthalmol. Vis. Sci. 25(3), 346-350 (1984).
29. Mannermaa E, Vellonen KS, Urtti A. Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv. Drug Deliv. Rev. 58(11), 1136-1163 (2006).
30. Hosoya K-i, Lee VHL, Kim K-J. Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation. Eur. J. Pharm. Biopharm. 60(2), 227-240 (2005).
31. Vandamme TF. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog. Retin. Eye Res. 21(1), 15-34 (2002).
32. Kaur IP, Garg A, Singla AK, Aggarwal D. Vesicular systems in ocular drug delivery: an overview. Int. J. Pharm. 269(1), 1-14 (2004).
33. Shirasaki Y. Molecular design for enhancement of ocular penetration. J. Pharm. Sci. 97(7), 2462-2496 (2008).
34. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intraviterous injection: a comprehensive review. Retina 24(5), 676-698 (2004).
35. Flaxel CJ. The use of systemic steroids and photodynamic treatment for choroidal neovascularisation in young patients. Br. J. Ophthalmol. 91(5), 564-565 (2007).
36. Masuda K, Urayama A, Kogure M et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet 333(8647), 1093-1096 (1989).
37. Pitkanen L, Ranta V-P, Moilanen H, Urtti A. Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity. Invest. Ophthalmol. Vis. Sci. 46(2), 641-646 (2005).
38. Eljarrat-Binstock E, Domb AJ. Iontophoresis: A non-invasive ocular drug delivery. J. Control. Release 110(3), 479-489 (2006).
39. Fattal E, Bochot Al. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. Adv. Drug Deliv. Rev. 58(11), 1203-1223 (2006).
40. Lee SS, Yuan P, Robinson MR. Ocular implants for drug delivery. In: Encyclopedia of Biomaterials and Biomedical Engineering. Wnek GE, Bowlin GL (Eds). Informa HealthCare, London, UK, 1105-1119 (2004).
41. Kimura H, Ogura Y. Biodegradable polymers for ocular drug delivery. Ophthalmologica 215(3), 143-155 (2001).
42. Saettone MF, Salminen L. Ocular inserts for topical delivery. Adv. Drug Deliv. Rev. 16(1), 95-106 (1995).
43. Baeyens V, Felt-Baeyens O, Rougier S et al. Clinical evaluation of bioadhesive ophthalmic drug inserts (BODI®) for the treatment of external ocular infections in dogs. J. Control. Release 85(1-3), 163-168 (2002).
44. Mahe I, Mouly S, Jarrin I et al. Efficacy and safety of three ophthalmic inserts for topical anaesthesia of the cornea. An exploratory comparative dose-ranging, double-blind, randomized trial in healthy volunteers. Br. J. Clin. Pharmacol. 59(2), 220-226 (2005).
45. Rabowsky JH, Dukes AJ, Lee DA, Leong KW. The use of bioerodible polymers and daunorubicin in glaucoma filtration surgery. Ophthalmology 103(5), 800-807 (1996).
46. Trope GE, Cheng YL, Sheardown H et al. Depot drug delivery system for 5-fluorouracil after filtration surgery in the rabbit. Can. J. Ophthalmol. 29(6), 263-267 (1994).
47. Kim Y-M, Lim J-O, Kim H-K, Kim S-Y, Shin J-P. A novel design of one-side coated biodegradable intrascleral implant for the sustained release of triamcinolone acetonide. Eur. J. Pharm. Biopharm. 70(1), 179-186 (2008).
48. Yasukawa T, Kimura H, Tabata Y, Ogura Y. Biodegradable scleral plugs for vitreoretinal drug delivery. Adv. Drug Deliv. Rev. 52(1), 25-36 (2001).
49. Avitabile T, Marano F, Castiglione F et al. Biocompatibility and biodegradation of intravitreal hyaluronan implants in rabbits. Biomaterials 22(3), 195-200 (2001).
50. Sakurai E, Matsuda Y, Ozeki H et al. Scleral plug of biodegradable polymers containing ganciclovir for experimental cytomegalovirus retinitis. Invest. Ophthalmol. Vis. Sci. 42(9), 2043-2048 (2001).
51. Felt-Baeyens O, Eperon S, Mora P et al. Biodegradable scleral implants as new triamcinolone acetonide delivery systems. Int. J. Pharm. 322(1-2), 6-12 (2006).
52. Miyamoto H, Ogura Y, Hashizoe M et al. Biodegradable scleral implant for intravitreal controlled release of fluconazole. Curr. Eye Res. 16, 930-935 (1997).
53. McGuire DE, McAulife P, Heinemann MH, Rahhal FM. Efficacy of the ganciclovir implant in the setting of silicone oil vitreous substitute. Retina 20(5), 520-523 (2000).
54. Chang M, Dunn JP. Ganciclovir implant in the treatment of cytomegalovirus retinitis. Expert Rev. Med. Devices 2(4), 421-427 (2005).
55. Ramchandran RS, Fekrat S, Stinnett SS, Jaffe GJ. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results. Am. J. Ophthalmol. 146(2), E281-E291 (2008).
56. Chieh JJ, Carlson AN, Jaffe GJ. Combined fluocinolone acetonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis. Am. J. Ophthalmol. 146(4), 589-594 (2008).
57. Emerich DF, Thanos CG. NT-501: an ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells. Curr. Opin. Mol. Ther. 10(5), 506-515 (2008).
58. Bucolo C, Maltese A, Drago F. When nanotechnology meets the ocular surface. Expert Rev. Ophthalmol. 3(3), 325-332 (2008).
59. Herrero-Vanrell R, Refojo MF. Biodegradable microspheres for vitreoretinal drug delivery. Adv. Drug Deliv. Rev. 52(1), 5-16 (2001).
60. Vasir JK, Tambwekar K, Garg S. Bioadhesive microspheres as a controlled drug delivery system. Int. J. Pharm. 255(1-2), 13-32 (2003).
61. Wischke C, Schwendeman SP. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int. J. Pharm. (2008).
62. Makino K, Mogi T, Ohtake N et al. Pulsatile drug release from poly (lactide-co-glycolide) microspheres: how does the composition of the polymer matrices affect the time interval between the initial burst and the pulsatile release of drugs? Colloids Surf. B Biointerfaces 19(2), 173-179 (2000).
63. Zimmer A, Kreuter J. Microspheres and nanoparticles used in ocular delivery systems. Adv. Drug Deliv. Rev. 16(1), 61-73 (1995).
64. Chiang CH, Tung SM, Lu DW, Yeh MK. In vitro and in vivo evaluation of an ocular delivery system of 5-fluorouracil microspheres. J. Ocul. Pharmacol. Ther. 17(6), 545-553 (2001).
65. Cui L-J, Sun N-X, Li X-H, Huang J, Yang J-G. Subconjunctival sustained release 5-fluorouracil for glaucoma filtration surgery. Acta Pharmacol. Sin. 29(9), 1021-1028 (2008).
66. Adibkia K, Omidi Y, Siahi MR et al. Inhibition of endotoxin-induced uveitis by methylprednisolone acetate nanosuspension in rabbits. J. Ocul. Pharmacol. Ther. 23(5), 421-432 (2007).
67. Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int. J. Pharm. 340(1-2), 126-133 (2007).
68. Harper CA, Khoobehi B, Peyman GA, Gebhardt BM, Dunlap WA. Bioavailability of microsphere-entrapped cyclosporine A in the cornea and aqueous of rabbits. Int. Ophthalmol. 17(6), 337-340 (1993).
69. Carrasquillo KG, Ricker JA, Rigas IK et al. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest. Ophthalmol. Vis. Sci. 44(1), 290-299 (2003).
70. Bourges J-L, Gautier SE, Delie F et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest. Ophthalmol. Vis. Sci. 44(8), 3562-3569 (2003).
71. Sakai T, Kuno N, Takamatsu F et al. Prolonged protective effect of basic fibroblast growth factor-impregnated nanoparticles in Royal College of Surgeons rats. Invest. Ophthalmol. Vis. Sci. 48(7), 3381-3387 (2007).
72. Jani PD, Singh N, Jenkins C et al. Nanoparticles sustain expression of fit intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest. Ophthalmol. Vis. Sci. 48(5), 2030-2036 (2007).
73. Farjo R, Skaggs J, Quiambao AB, Cooper MJ, Naash MI. Efficient non-viral ocular gene transfer with compacted DNA nanoparticles. PLoS ONE 1(1), E38 (2006).
74. Fattal E, Bochot A. State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers. Int. J. Pharm. 364(2), 237-248 (2008).
75. Raju HB, Goldberg JL. Nanotechnology for ocular therapeutics and tissue repair. Expert Rev. Ophthalmol. 3(4), 431-436 (2008).
76. Amrite AC, Edelhauser HF, Singh SR, Kompella UB. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol. Vis. 14, 150-160 (2008).
77. Alvarez-Lorenzo C, Hiratani H, Concheiro A. Contact lenses for drug delivery: achieving sustained release with novel systems. Am. J. Drug Deliv. 4(3), 131-151 (2006).
78. Xinming L, Yingde C, Lloyd AW et al. Polymeric hydrogels for novel contact lens-based ophthalmic drug delivery systems: a review. Cont. Lens Anterior Eye 31(2), 57-64 (2008).
79. Karlgard CCS, Wong NS, Jones LW, Moresoli C. In vitro uptake and release studies of ocular pharmaceutical agents by silicon-containing and p-HEMA hydrogel contact lens materials. Int. J. Pharm. 257(1-2), 141-151 (2003).
80. Bucolo C, Mangiafico S, Spadaro A. Methylprednisolone delivery by Hyalobend® corneal shields and its effects on rabbit ocular inflammation. J. Ocul. Pharmacol. Ther. 12(2), 141-149 (1996).
81. Unterman SR, Rootman DS, Hill JM et al. Collagen shield drug delivery: therapeutic concentrations of tobramycin in the rabbit cornea and aqueous humor. J. Cataract Refract. Surg. 14(5), 500-504 (1988).
82. O'Brien TP, Sawusch MR, Dick JD, Hamburg TR, Gottsch JD. Use of collagen corneal shields versus soft contact lenses to enhance penetration of topical tobramycin. J. Cataract Refract. Surg. 14(5), 505-507 (1988).
83. Willoughby CE, Batterbury M, Kaye SB. Collagen corneal shields. Surv. Ophthalmol. 47(2), 174-182 (2002).
84. Parmar DN, Alizadeh H, Awwad ST et al. Ocular surface restoration using non-surgical transplantation of tissue-cultured human amniotic epithelial cells. Am. J. Ophthalmol. 141(2), 299-307 (2006).
85. Greenwald Y, Kleinmann G. Use of collagen shields for ocular-surface drug delivery. Expert Rev. Ophthalmol. 3(6), 627-633 (2008).
86. dos Santos J-FR, Couceiro R, Concheiro A, Torres-Labandeira J-J, Alvarez-Lorenzo C. Poly(hydroxyethyl methacrylate-co-methacrylated-[β]-cyclodextrin) hydrogels: synthesis, cytocompatibility, mechanical properties and drug loading/ release properties. Acta Biomater. 4(3), 745-755 (2008).
87. Uchida R, Sato T, Tanigawa H, Uno K. Azulene incorporation and release by hydrogel containing methacrylamide propyltrimenthylammonium chloride, and its application to soft contact lens. J. Control. Release 92(3), 259-264 (2003).
88. Ali M, Horikawa S, Venkatesh S et al. Zero-order therapeutic release from imprinted hydrogel contact lenses within in vitro physiological ocular tear flow. J. Control. Release 124(3), 154-162 (2007).
89. Hiratani H, Alvarez-Lorenzo C. Timolol uptake and release by imprinted soft contact lenses made of N, N-diethylacrylamide and methacrylic acid. J. Control. Release 83(2), 223-230 (2002).
90. Mullarney MP, Seery TAP, Weiss RA. Drug diffusion in hydrophobically modified N, N-dimethylacrylamide hydrogels. Polymer 47(11), 3845-3855 (2006).
91. Gulsen D, Chauhan A. Dispersion of microemulsion drops in HEMA hydrogel: a potential ophthalmic drug delivery vehicle. Int. J. Pharm. 292(1-2), 95-117 (2005).
92. Li C-C, Abrahamson M, Kapoor Y, Chauhan A. Timolol transport from microemulsions trapped in HEMA gels. J. Colloid Interface Sci. 315(1), 297-306 (2007).
93. Tetz MR, Ries MW, Lucas C, Stricker H, Volcker HE. Inhibition of posterior capsule opacification by an intraocular-lens-bound sustained drug delivery system: an experimental animal study and literature review. J. Cataract Refract. Surg. 22(8), 1070-1078 (1996).
94. Kim HC, Härtner S, Hampp N. Single-and two-photon absorption induced photocleavage of dimeric coumarin linkers: therapeutic versus passive photocleavage in ophthalmologic applications. J. Photochem. Photobiol. A Chem. 195(2-3), 239-244 (2008).
95. Kleinmann G, Apple DJ, Chew J et al. Hydrophilic acrylic intraocular lens as a drug-delivery system for fourth-generation fluoroquinolones. J. Cataract Refract. Surg. 32(10), 1717-1721 (2006).
96. Eperon S, Bossy-Nobs L, Petropoulos IK, Gurny R, Guex-Crosier Y. A biodegradable drug delivery system for the treatment of postoperative inflammation. Int. J. Pharm. 352(1-2), 240-247 (2008).
97. Matsushima H, Iwamoto H, Mukai K et al. Preventing secondary cataract and anterior capsule contraction by modification of intraocular lenses. Expert Rev. Med. Devices 5(2), 197-207 (2008).
98. Jacob JT, LaCour OJ, Burgoyne CF. Slow release of the antimetabolite 5-fluorouracil (5-FU) from modified Baerveldt glaucoma drains to prolong drain function. Biomaterials 22(24), 3329-3335 (2001).
99. Araiz JJ, Refojo MF, Arroyo MH et al. Antiproliferative effect of retinoic acid in intravitreous silicone oil in an animal model of proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 34(3), 522-530 (1993).
100. Steffansen B, Ashton P, Buur A. Intraocular drug delivery. In vitro release studies of 5-fluorouracil from N1-alkoxycarbonyl prodrugs in silicone oil. Int. J. Pharm. 132(1-2), 243-250 (1996).
101. Jolimaitre P, Malet-Martino M, Martino R. Fluorouracil prodrugs for the treatment of proliferative vitreoretinopathy: formulation in silicone oil and in vitro release of fluorouracil. Int. J. Pharm. 259(1-2), 181-192 (2003).
102. Zhang G, Feng X, Wabner K et al. Intraocular nanoparticle drug delivery: a pilot study using an aerosol during pars plana vitrectomy. Invest. Ophthalmol. Vis. Sci. 48(11), 5243-5249 (2007).